ISRCTN33429693已完成未知
A randomised clinical trial comparing hydrocolloid, phenytoin and simple dressing in the treatment of pressure ulcer
Janbazan Medical and Engineering Research Centre (JMERC)0 个研究点目标入组 83 人开始时间: 2004年10月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 83
研究概览
简要总结
2004 results in http://www.ncbi.nlm.nih.gov/pubmed/15601464
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •Current information as of 19/08/09:
- •1. Paraplegia caused by spinal cord injury
- •2. Pressure ulcer stage I and II according to Shea classification or National Pressure Ulcer Advisory Panel
- •3. Patient's informed consent
- •4. Smoothness of ulcer area to establish whether adhesive could be used at the site
- •Initial information at time of registration:
- •83 spinal cord victims of IRAN-IRAQ with pressure ulcer
排除标准
- •Added 19/08/09:
- •1. Addiction
- •2. Heavy smoking (more than 20 cigarettes a day or more than 10 packs per year
- •3. Concomitant chronic disease (e.g. diabetes mellitus or frank vascular disease such as Buerger's disease)
研究者
相似试验
已完成
不适用
Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product.Herpes Simplex LabialisNCT02157090Technische Universität Dresden
招募中
不适用
Silver containing dressing in wound management.IRCT20221210056768N1Iran University of Medical Sciences42
已完成
不适用
Clinical comparison study between newly developed FFR device based on optical interferometry and conventional FFR devicecoronary artery disease patientsJPRN-UMIN000028268Department of Cardiology Aichi Medical University51
已完成
不适用
Randomised controlled trial comparing two treatment methods for symptomatic haemorrhoidal diseaseHaemorrhoidsCircumferential grade II symptomatic haemorrhoidsCirculatory SystemISRCTN23585705niversity of Aberdeen Medicines Assessment Research Unit (MARU)60
终止
4 期
Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH)Congenital HypothyroidismNCT05228184IBSA Institut Biochimique SA34